New Treatment Offers Benefit for Hypoxic Laryngeal Tumors

Share this article:
New Treatment Offers Benefit for Hypoxic Laryngeal Tumors
New Treatment Offers Benefit for Hypoxic Laryngeal Tumors

(HealthDay News) – For patients with squamous cell laryngeal cancer, regional control rates are improved with accelerated radiotherapy (AR) plus carbogen inhalation and nicotinamide (ARCON) treatment compared with AR-alone, with the improvement seen in patients with hypoxic tumors, according to research published online April 16 in the Journal of Clinical Oncology.

Geert O. Janssens, MD, of the Radboud University Nijmegen Medical Centre in the Netherlands, and colleagues conducted a Phase 3 randomized study involving 345 patients with cT2-4 squamous cell laryngeal cancer who were treated with either AR, which consisted of 68 Gy within 36–38 days, or ARCON, which included 64 Gy on the laryngeal cartilage. In a side study, the oxygenation status was assessed in tumor biopsies using pimonidazole.

After a median follow-up of 44 months, the researchers found that the local tumor control rate was similar for AR and ARCON (78% and 79%, respectively; P=0.80), with similar larynx preservation rates (84% and 87%, respectively; P=0.48). However, the secondary end point, five-year regional control, was significantly better with ARCON versus AR (93% vs. 86%; P=0.04). Improved regional control was only observed in patients with hypoxic, not well-oxygenated, tumors. No difference in treatment-related toxicity between the AR and ARCON regimens was observed.

"The use of ARCON in Stage II–IV laryngeal cancer produced a significant gain in regional control rate compared with AR, with similar acute and late toxicity," the authors write. "Proper patient selection based on tumor biology is key to the success of this approach."

Abstract
Full Text (subscription or payment may be required)
Editorial

This article originally appeared here.
Share this article:

Related Resources